arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Bristol-Myers Squibb Company

BMY Health Care Biotechnology: Pharmaceutical Preparations
$67.01
▲ +0.3% Today
as of Sep 4, 16:46 ET
Last 30 days +5.06% Jul 28 → Sep 04
$62.70 $64.15 $65.59 $67.04 $68.49 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$67.24
High
$67.72
Low
$66.58
Volume
$5M
Avg Vol
$13M
Mkt Cap
$131.0B
P/E (TTM)
16.60
Beta
—
52w High
$68.64
52w Low
$42.52
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 3 ● 21 ▼ 1
Sep 4 · 21:45 Zacks neutral
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Sep 4 · 19:36 Zacks neutral
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Sep 3 · 15:39 Barchart neutral
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$43
$69
94% of range
Avg surprise (last 2)
+27.8%
Avg reaction (last 1)
+0.3%
100% positive
Latest IV / EM
31%
EM ±1.3% · $68 · Sep 4

Earnings trends

EPS — actual vs estimate Actual Estimate
$-5.89$-3.97$-2.04$-0.12$1.80 Actual $1.07Actual $0.99Actual $0.93Actual $-5.89Actual $0.83Actual $0.60Actual $1.80Est $1.51Actual $1.46Est $1.07Actual $1.08Actual $1.31Actual $1.62 MarJunSepMarJunSepMar/2025Jun/2025SepMarJun
Revenue vs Net Income Revenue Net income
$0$3.4B$6.8B$10.2B$13.6B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $1.62 — — — — financials
Tue Mar 31, 2026Mar 2026 $1.31 — — — — financials
Tue Sep 30, 2025Sep 2025 $1.08 — — — — financials
Thu Jul 31, 2025Jun/2025 $1.46 $1.07 +36.5% — — earnings
Thu Apr 24, 2025Mar/2025 $1.80 $1.51 +19.2% — +0.3% earnings
Mon Sep 30, 2024Sep 2024 $0.60 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.83 — — — — financials
Sun Mar 31, 2024Mar 2024 $-5.89 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.93 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.99 — — — — financials
Fri Mar 31, 2023Mar 2023 $1.07 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$12.97B$11.49B—$12.22B$12.27B$11.20B—$11.89B
Cost of revenue$3.73B$3.42B—$3.44B$3.37B$3.03B—$2.96B
Gross profit————————
Operating income————————
Net income$3.32B$2.68B—$2.20B$1.31B$2.46B—$1.21B
EPS (diluted)$1.62$1.31—$1.08$0.64$1.20—$0.60

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$8.72B$9.57B$10.21B$15.73B$12.60B$10.88B$10.35B$7.89B
Inventory$2.74B$2.76B$2.69B$2.76B$2.74B$2.67B$2.56B$3.33B
Total current assets$28.58B$27.21B$29.39B$35.63B$33.22B$30.78B$29.78B$28.07B
Total assets$87.63B$86.48B$90.04B$96.89B$94.68B$92.43B$92.60B$93.67B
Long-term debt$42.09B$42.15B$42.85B$44.47B$44.47B$46.16B$47.60B$48.67B
Total liabilities$65.31B$66.37B$71.53B$78.29B$77.19B$74.98B$76.22B$76.47B
Total equity$22.32B$20.07B$18.47B$18.55B$17.43B$17.39B$16.34B$17.14B

Implied volatility — last 90 days

24%34%45%55%65% Jun 07 — IV 38% · EM ±3.5%Jun 08 — IV 31% · EM ±2.6%Jun 09 — IV 33% · EM ±2.4%Jun 10 — IV 35% · EM ±2.0%Jun 11 — IV 38% · EM ±1.6%Jun 15 — IV 32% · EM ±2.3%Jun 16 — IV 31% · EM ±1.9%Jun 17 — IV 37% · EM ±1.5%Jun 19 — IV 27% · EM ±3.0%Jun 22 — IV 31% · EM ±2.6%Jun 23 — IV 30% · EM ±2.2%Jun 24 — IV 30% · EM ±1.8%Jun 25 — IV 41% · EM ±1.7%Jun 29 — IV 32% · EM ±7.5%Jun 30 — IV 33% · EM ±7.6%Jul 01 — IV 32% · EM ±7.4%Jul 02 — IV 31% · EM ±7.0%Jul 03 — IV 32% · EM ±7.0%Jul 06 — IV 33% · EM ±6.9%Jul 07 — IV 33% · EM ±6.7%Jul 08 — IV 33% · EM ±6.7%Jul 09 — IV 33% · EM ±6.5%Jul 10 — IV 32% · EM ±6.2%Jul 13 — IV 37% · EM ±6.5%Jul 14 — IV 48% · EM ±8.3%Jul 15 — IV 36% · EM ±6.1%Jul 16 — IV 38% · EM ±6.2%Jul 17 — IV 40% · EM ±6.2%Jul 20 — IV 42% · EM ±5.8%Jul 21 — IV 42% · EM ±5.6%Jul 22 — IV 40% · EM ±5.0%Jul 23 — IV 42% · EM ±5.0%Jul 24 — IV 44% · EM ±4.9%Jul 27 — IV 57% · EM ±4.7%Jul 28 — IV 60% · EM ±4.4%Jul 29 — IV 66% · EM ±3.9%Jul 30 — IV 33% · EM ±1.4%Aug 03 — IV 40% · EM ±3.4%Aug 04 — IV 55% · EM ±3.9%Aug 05 — IV 36% · EM ±2.1%Aug 06 — IV 36% · EM ±1.5%Aug 10 — IV 28% · EM ±2.4%Aug 11 — IV 25% · EM ±1.8%Aug 12 — IV 30% · EM ±1.8%Aug 13 — IV 30% · EM ±1.3%Aug 17 — IV 28% · EM ±2.4%Aug 18 — IV 33% · EM ±2.4%Aug 19 — IV 37% · EM ±2.2%Aug 20 — IV 61% · EM ±2.6%Aug 24 — IV 30% · EM ±2.5%Aug 25 — IV 36% · EM ±2.6%Aug 26 — IV 31% · EM ±1.9%Aug 27 — IV 30% · EM ±1.2%Aug 31 — IV 26% · EM ±2.2%Sep 01 — IV 27% · EM ±1.9%Sep 02 — IV 31% · EM ±1.8%Sep 03 — IV 31% · EM ±1.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in